linjc16/ctgov huggingface dataset:
Is Abrasion of the Suture Area Essential for Healing of a Meniscus Lesion?

Study Overview
=================
Brief Summary
-----------------
The most common technique involves a suture meniscus avivement with a rasp or a motorized cutter the suture zone before actual implementation of the suture. But the imperative nature of this avivement is based only on theoretical considerations. The team has an old experience in conducting meniscus sutures without avivement. It therefore seems interesting to compare results with those of literature

Official Title
-----------------
Does the Avivement of Suturing Area is Essential for Healing a Meniscus Lesion ?

Conditions
-----------------
Meniscus Lesion

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients over 18 years Patients who underwent meniscal suturing with or without avivement Exclusion Criteria: Patients under 18 years

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Healing meniscus suturing area |  | For the duration of hospital stay, up to 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Lesion, Meniscus, Avivement, Suturing area
Cancer Pain Single Nucleotide Polymorphisms (SNPs)

Study Overview
=================
Brief Summary
-----------------
Cancer pain is common in advanced cancer patients. Opioids are the mainstay of treatment in cancer pain. Responsiveness to and tolerability of opioids is, amongst others, determined by small variations in human DNA. Using blood samples from clinically well-defined cancer pain patients, the investigators are going to analyze single nucleotide polymorphisms (SNPs) in genes that are known to be involved in responsiveness to opioids and sensitivity to pain.

Official Title
-----------------
Storage and Analysis of Patient Blood-samples for Cancer Pain Research

Conditions
-----------------
Cancer, Pain

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Cancer pain patients Exclusion Criteria: Patients not able to provide informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Cancer Pain Patients<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| correlation between pain SNPs and equianalgesic opioid requirement | candidate SNP analysis | timepoint at blood sample | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cancer, Pain, SNP
Use of Self-management Group to Improve Quality of Life in Patients With Low Vision

Study Overview
=================
Brief Summary
-----------------
120 Patients with visual acuity <6/12 will be randomized to receive either usual care or participate in a 6-week, 2 hour 'Living with Vision Loss' program led by trained leaders. We hypothesize that a structured self-management low-vision rehabilitation program provides a greater improvement in participation in daily activities, and improves quality of life in vision-impaired people compared to the provision of the usual low vision rehabilitation services. We also plan to document barriers that prevent patients with low vision (visual acuity <6/12) from participating in self-management course.

Official Title
-----------------
A Randomized Controlled Trial to Assess if Attending an Interactive, Self-management Group, 'Living With Vision Loss', in Addition to Having Vision Rehabilitation in Our Clinic, Improves Patients' Quality of Life

Conditions
-----------------
Age Related Macular Degeneration

Intervention / Treatment
-----------------
* Behavioral: Self management program 'Living with Vision Loss'


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clients who have attended the MEEI Vision Rehabilitation for the first time within 12 months Visual acuity of <6/12 in the better eye with habitual correction Age 55+ years Living independently (not in a nursing home) English speaking No cognitive impairment Adequate hearing to respond to normal conversation Exclusion Criteria: vestibular disease

Ages Eligible for Study
-----------------
Minimum Age: 55 Years
Maximum Age: 95 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Self management program<br>Self management program 'Living with Vision Loss' 6 week course that met for 2 hours each week led by a trained leader. | Behavioral: Self management program 'Living with Vision Loss'<br>* group met for 6 weeks, 2 hours per week, to discuss strategies for living with low vision<br>|
| No Intervention: Wait list control<br>Wait list control | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Impact of Vision Impairment Questionnaire (IVI) |  | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
AMD, vision loss, self-management strategies, low-vision rehabilitation, IVI
Study Evaluating The Excretion Of Moxidectin Into The Breast Milk Of Lactating, Non-Breastfeeding Women

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the extent of moxidectin transfer into the breast milk of lactating women and to provide the initial pharmacokinetic and safety profile of moxidectin in lactating women.

Official Title
-----------------
An Open-Label, Single-Dose Study to Evaluate the Excretion of Moxidectin Into the Breast Milk of Lactating, Non-breastfeeding Women.

Conditions
-----------------
Infection

Intervention / Treatment
-----------------
* Drug: Moxidectin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Healthy lactating women aged 21 to 45 years inclusive at screening. Women should: Be at least 12-weeks postpartum after uncomplicated delivery with a full milk supply established. Be willing to discontinue breastfeeding permanently and should be in the process of weaning their infant. Care should be taken to ensure that subjects have not discontinued breastfeeding an infant in order to participate in the study. Not plan to breastfeed within 9 months of study drug administration. Be willing to fully express breast milk from both breasts during the duration of the milk collection portion of the study. Subjects must be able to express milk from each breast at each pumping session using a breast pump. Body mass index in the range of 18 to 35 kg/m2. Exclusion criteria: Presence or history of any disorder that may prevent the successful completion of the study. Any significant cardiovascular, hepatic, renal, respiratory, gastrointestinal, endocrine, immunologic, dermatologic, hematologic, neurologic, or psychiatric disease.

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br> | Drug: Moxidectin<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Blood samples |  | 4 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety based on adverse event monitoring, vital sign measurements, 12-lead ECGs and routine lab tests. |  | 4 months |
Randomized Trial of Intranasal Versus Intravenous Naloxone in Level of Consciousness in Suspected Opioid Overdose

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine which route of administration is better for treatment of opioid overdosed patients

Detailed Description
-----------------
In intravenous drug abusers (IDUs), as a result of previous intravenous substance abuse, the predictable difficult cannulate exist and cause the delay administration of antidote therapy. Additionally, IDUs are also at increased risk of carrying blood borne infections that could be transmitted to healthcare workers through needle stick injuries. The investigators aimed to compare intranasal administration of naloxone with intravenous route.

Official Title
-----------------
Study of Routs of Naloxone Administration for Opioid Overdosed Patients

Conditions
-----------------
Morphinan Opioid Overdose

Intervention / Treatment
-----------------
* Drug: Intranasal naloxone
* Drug: Intravenous


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with the range of 15-50 years old Who were suspicious to opioid overdoses based on history and having clinical appearance such as miotic pupils with loss of consciousness Give response to naloxone with increasing the level of consciousness Exclusion Criteria: Not giving response to naloxone and suspicious to have another reason for loss of consciousness

Ages Eligible for Study
-----------------
Minimum Age: 15 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Intravenous<br>The investigators administered intravenous naloxone for our opioid overdose patients | Drug: Intravenous<br>* Amp naloxone, 0.4 mg / each 4 minutes till increasing patient level of consciousness<br>|
| Other: Intranasal<br>The investigators administered intranasal naloxone for treatment of our patients | Drug: Intranasal naloxone<br>* spray naloxone, 0.4 mg/ each 4 minutes till increasing patient level of consciousness<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| level of consciousness | The investigators evaluated the level of consciousness with Glasgow coma sclae 4 minutes after naloxone administration | 4 min after naloxone administration | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| blood pressure | The investigators evaluated blood pressure 4 minutes after naloxone administration | at 4 min after naloxone administration | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
opioid, overdose, naloxone, intranasal
Effect of Rosiglitazone on ADMA in Critical Illness

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether Rosiglitazone,decreases the ADMA concentration and thereby increases the arginine/ADMA ratio of critically ill patients.

Detailed Description
-----------------
Endothelial vasodilatation dysfunction precedes the development of arteriosclerosis. The endothelium plays a pivotal role in the control of the vascular tone by releasing nitric oxide (NO). The amino acid arginine is the sole substrate for the enzyme NO synthase (NOS). Asymmetric dimethylarginine (ADMA) is an endogenous derivative of arginine that inhibits NOS. Thus the arginine/ADMA ratio an important determinant of NO production by NOS. ADMA is an independent risk factor for cardiovascular disease, but elevated levels of ADMA have also been shown to be a strong independent predictor of ICU mortality. The central mechanism by which ADMA may cause deterioration in critically ill patients is by impairing organ blood flow and reducing cardiac function, especially during stress. Accumulation of ADMA could thereby be a causative factor in the development multi organ failure (MOF). Thus inhibition of NO production by ADMA may become especially important when cardiac demand is increased.

Conditions
-----------------
Critical Illness, Multiple Organ Failure

Intervention / Treatment
-----------------
* Drug: Rosiglitazone


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: critically ill patients age between 18 and 75 years SOFA score > 7 Exclusion Criteria: history of Diabetes mellitus history of hypercholesterolemia history of hyperhomocysteinemia impaired hepatic function

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Rosiglitazone|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| ADMA concentration |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| SOFA score |  |  | 
| Organ function |  |  | 
| Mortality |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
ADMA, MOF, Critical illness
Efficacy of a Modified Obturator Nerve Block Technique

Study Overview
=================
Brief Summary
-----------------
Efficacy of a modified obturator nerve block technique by using only a single morphological landmark, a double-blinded randomised pilot study.

Conditions
-----------------
Hip Surgery, Knee Surgery

Intervention / Treatment
-----------------
* Procedure: obturator nerve block


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: American Society of Anesthesiologists 1-3, older than 18 y, cooperative patient Exclusion Criteria: infection, neuromuscular deficits of the lower extremities,pregnancy, neurologic disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Ropivacain<br>Local anaesthesia | Procedure: obturator nerve block<br> <br> |
| Placebo Comparator: NaCl 0.9%<br>Saline | Procedure: obturator nerve block<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adductor strengths | Adductor muscle strength is measured with a sphygmomanometer. Patients are instructed to squeeze a blod pressure cuff, already inflated to 40 mm Hg, between their extended knees. The maximal sustained pressure is taken as the baseline adductor strength. | pre operative, 30 minutes before start surgery |
A Phase II Study of KCT-0809 in Patients With Dry Eye Syndrome

Study Overview
=================
Brief Summary
-----------------
To evaluate the efficacy and safety of KCT-0809 compared to placebo in patients with dry eye syndrome.

Official Title
-----------------
A Randomized, Double Blind, Placebo Controlled, Phase II Study of KCT-0809 in Patients With Dry Eye Syndrome

Conditions
-----------------
Dry Eye Syndromes

Intervention / Treatment
-----------------
* Drug: KCT-0809
* Drug: KCT-0809
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Corneal and conjunctival damage Insufficiency of lacrimal secretion Ocular symptom Exclusion Criteria: Severe ophthalmic disorder Punctual plugs or surgery for occlusion of the lacrimal puncta

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: KCT-0809 ophthalmic solution, low dose<br> | Drug: KCT-0809<br> <br> |
| Experimental: KCT-0809 ophthalmic solution, high dose<br> | Drug: KCT-0809<br> <br> |
| Placebo Comparator: Placebo<br> | Drug: Placebo<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Corneal staining score |  | 6 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Conjunctival staining score |  | 6 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Dry eye syndromes, Corneal diseases, Conjunctival diseases
Lymphocytic Herpesviruses and Cerebrospinal Fluid Polymerase Chain Reaction (PCR)

Study Overview
=================
Brief Summary
-----------------
Enterovirus and herpes simplex viruses 1 and 2 are the main causative agents of central nervous system infections. Instead, the role of lymphocytic herpesviruses in the etiology of central nervous system (CNS) infections is not clear, even if there is the positive cerebrospinal fluid (CSF) polymerase chain reaction (PCR)-result for the virus. The aim of this study is to evaluate the presence of DNA from lymphocytic herpesviruses in the CSF obtained from the immunocompetent patients with CSF pleocytosis and from the patients with normal CSF leukocyte count.

Official Title
-----------------
Molecular Methods in the Etiological Diagnostics of Acute Central Nervous System Infections: Lymphocytic Herpesviruses and PCR

Conditions
-----------------
Central Nervous System Infection

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Immunocompetent patients with clinical symptoms and signs of central nervous system infections and CSF pleocytosis (pleocytosis group) Immunocompetent patients without suspicion of CNS infection and no CSF pleocytosis (non-pleocytosis group) Exclusion Criteria: Suspicion of CNS-infection, eg. encephalitis, but no CSF leukocytosis (pleocytosis group) Patients without symptoms of CNS infection, but who has CSF pleocytosis of unknown origin (non-pleocytosis group)

Ages Eligible for Study
-----------------
Minimum Age: 16 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| pleocytosis group<br>40 patients with clinical signs of CNS infection and having CSF pleocytosis. | |
| non-pleocytosis group<br>20 patients not having CNS infection clinically and not having CSF pleocytosis. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
CSF, PCR, lymphocytic herpesvirus, CNS
Using RCT to Increase Completion Rates of the Health Assessment Questionnaire.

Study Overview
=================
Brief Summary
-----------------
The proposed study aims to examine several iterations of instructions/reminders that patients receive for completing the Health Assessment Questionnaire (self-reported health outcomes) for their outpatient visit at NYU Langone Orthopedic Center. The goal is to increase the completion rates of patient-reported health outcomes.

Official Title
-----------------
Using Rapid Cycle Randomized Controlled Trials to Increase Completion Rates of the Patient-Reported Health Assessment Questionnaire During Outpatient Visits at NYU Langone Orthopedic Center

Conditions
-----------------
Patient-reported Outcomes

Intervention / Treatment
-----------------
* Other: Arm A
* Other: Arm B


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients who are eligible to receive the Health Assessment Questionnaire in preparation for and during their outpatient visit to the NYU Langone Orthopedic Center. Exclusion Criteria: N/A
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Arm A<br>Participants in this group will receive one version (out of two) of instructions for completing the Health Assessment Questionnaire. | Other: Arm A<br>* Intervention includes various iterations of instructions for completing the Health Assessment Questionnaire. Participants in this group will receive one version (out of two) of instructions for completing the Health Assessment Questionnaire.<br>|
| Active Comparator: Arm B<br>Participants in this group will receive another version (out of two) of instructions for completing the Health Assessment Questionnaire. | Other: Arm B<br>* Intervention includes various iterations of instructions for completing the Health Assessment Questionnaire. Participants in this group will receive another version (out of two) of instructions for completing the Health Assessment Questionnaire.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Questionnaire Completion Rate (number of times patients complete or partially complete the questionnaire). | Completion rate data is routinely collected by the medical center. | Duration of the study, up to 6 months. |